Kane Biotech Stock Buy Hold or Sell Recommendation
| KNBIF Stock | USD 0.08 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Kane Biotech is 'Strong Sell'. Macroaxis provides Kane Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding KNBIF positions.
Check out Kane Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Kane and provide practical buy, sell, or hold advice based on investors' constraints. Kane Biotech. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Kane |
Execute Kane Biotech Buy or Sell Advice
The Kane recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kane Biotech. Macroaxis does not own or have any residual interests in Kane Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kane Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Kane Biotech Trading Alerts and Improvement Suggestions
| Kane Biotech generated a negative expected return over the last 90 days | |
| Kane Biotech has some characteristics of a very speculative penny stock | |
| Kane Biotech has high historical volatility and very poor performance | |
| Kane Biotech has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.61 M. Net Loss for the year was (4.6 M) with profit before overhead, payroll, taxes, and interest of 568.44 K. | |
| Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 27.0% of Kane Biotech outstanding shares are owned by corporate insiders |
Kane Biotech Returns Distribution Density
The distribution of Kane Biotech's historical returns is an attempt to chart the uncertainty of Kane Biotech's future price movements. The chart of the probability distribution of Kane Biotech daily returns describes the distribution of returns around its average expected value. We use Kane Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kane Biotech returns is essential to provide solid investment advice for Kane Biotech.
| Mean Return | -0.27 | Value At Risk | -2.81 | Potential Upside | 0.65 | Standard Deviation | 3.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kane Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Kane Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kane Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kane Biotech's price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kane otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | -0.04 | |
σ | Overall volatility | 3.45 | |
Ir | Information ratio | -0.11 |
Kane Biotech Volatility Alert
Kane Biotech exhibits very low volatility with skewness of -2.72 and kurtosis of 22.59. Kane Biotech is a penny stock. Although Kane Biotech may be in fact a good investment, many penny otc stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Kane Biotech. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Kane instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Kane Biotech Fundamentals Vs Peers
Comparing Kane Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kane Biotech's direct or indirect competition across all of the common fundamentals between Kane Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kane Biotech or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kane Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kane Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kane Biotech to competition |
| Fundamentals | Kane Biotech | Peer Average |
| Return On Equity | -5.97 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Profit Margin | (1.80) % | (1.27) % |
| Operating Margin | (1.72) % | (5.51) % |
| Current Valuation | 12.47 M | 16.62 B |
| Shares Outstanding | 124.83 M | 571.82 M |
| Shares Owned By Insiders | 26.82 % | 10.09 % |
| Price To Earning | 4.68 X | 28.72 X |
| Price To Book | 102.61 X | 9.51 X |
| Price To Sales | 3.45 X | 11.42 X |
| Revenue | 1.61 M | 9.43 B |
| Gross Profit | 568.44 K | 27.38 B |
| EBITDA | (4.25 M) | 3.9 B |
| Net Income | (4.6 M) | 570.98 M |
| Cash And Equivalents | 2.53 M | 2.7 B |
| Cash Per Share | 0.02 X | 5.01 X |
| Total Debt | 1.12 M | 5.32 B |
| Debt To Equity | 7.12 % | 48.70 % |
| Current Ratio | 0.67 X | 2.16 X |
| Book Value Per Share | (0.05) X | 1.93 K |
| Cash Flow From Operations | (2.29 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 18 | 18.84 K |
| Beta | 0.19 | -0.15 |
| Market Capitalization | 10.45 M | 19.03 B |
| Total Asset | 6.13 M | 29.47 B |
| Z Score | 5.4 | 8.72 |
| Net Asset | 6.13 M |
Kane Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kane . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Kane Biotech Buy or Sell Advice
When is the right time to buy or sell Kane Biotech? Buying financial instruments such as Kane OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Kane Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.